Evidence map›Paper›PMID 26579459›Full record

ReviewActa pharmaceutica Sinica. B2015

Current developments in pharmacological therapeutics for chronic constipation.

Chunhuan Jiang, Qinglong Xu, Xiaoan Wen, Hongbin Sun

Open access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Acta pharmaceutica Sinica. B, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
5.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. The Efficacy of Lubiprostone in Patients of Constipation: An Updated Systematic Review and Meta-Analysis.JGH open : an open access journal of gastroenterology and hepatology · 2025
    Review
  4. Observational
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Observational
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Chunhuan JiangState Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, China Pharmaceutical University, Nanjing 210009, China.
Qinglong XuState Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, China Pharmaceutical University, Nanjing 210009, China.
Xiaoan WenState Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, China Pharmaceutical University, Nanjing 210009, China.
Hongbin SunState Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Discovery for Metabolic Disease, China Pharmaceutical University, Nanjing 210009, China.
State Key Laboratory of Natural MedicineChina Pharmaceutical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic constipation is a common gastrointestinal disease severely affecting the patient׳s quality of life. The traditional treatment of constipation is the use of laxatives. Recently, several new drugs including lubiprostone, linaclotide and prucalopride have been approved for treatment of chronic constipation. However, a significant unmet medical need still remains, particularly among those patients achieving poor results by current therapies. The 5-HT4 receptor modulators velusetrag and naronapride, the guanylate cyclase C agonist plecanatide and the ileal bile acid transporter inhibitor elobixibat are recognized as the most promising drugs under investigation. Herein, we give a comprehensive review on the pharmacological therapeutics for the treatment of chronic constipation, with the purpose of reflecting the drug development trends in this field.

Indexed as

5-HT4 receptor5-HT, serotoninCaCC, calcium-activated chloride channelCC, chronic constipationCDCA, chenodeoxycholic acidCFTR, cystic fibrosis transmembrane conductance regulatorChronic constipationCIC, chronic idiopathic constipationClC-2, chloride channel protein 2ENaC, epithelial sodium channelGC-C, guanylate cyclase CGI, gastrointestinalhERG, human ether-à-go-go–related geneIBAT, the ileal bile acid transporter (also known as apical sodium-dependent bile acid transporter)IBS-C, irritable bowel syndrome with constipationIPAN, intrinsic primary afferent neuronsLGP, lubricating gut pillNHE3, sodium-hydrogen exchanger 3OIC, opioid-induced constipationPKGII, protein kinase IIProkinetic agentProsecretory agentSBMs, spontaneous bowel movementsTGR5, the G-protein-coupled bile acid receptor

Identifiers

PMID26579459
PMCPMC4629408
OpenAlexW649893199

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.